INSIDE THE FUTURE
As the imaging industry changes, so do we. With a strong dedication to research and development, we continually look for innovative ways to ensure we deliver the highest quality products to our global customers. Mallinckrodt is here for the long term, with a legacy of proven innovation and a steadfast commitment to our customers, clinical excellence and a bold reinvestment in the future of imaging.
As one of the few companies in the world to reinvest in nuclear medicine, we stand at the threshold of its exciting future. Mallinckrodt is continuously making investments to increase worldwide supply stability of Mo-99 by constantly evaluating all potential long-term global supply opportunities and solutions. We are leading the industry with significant investment in our internal generator shielding that provides a lower radiation exposure alternative.
We invest in the future of contrast media through continued enhancements to RFID technology, and in urology as we advance the technology behind our Liebel-Flarsheim™ imaging systems.
We are committed to fostering innovation through our substantial investment in R&D. We have ambitious goals for the future and are putting 100% of those efforts into meeting them. With our strong commitment to people, the community, the environment and our products, we have a clear view insidethe future of imaging.
Mallinckrodt, the “M” brand mark, and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2015 Mallinckrodt.
Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at Damastown, Mulhuddart, Dublin 15, Ireland.